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BIOTECHNOLOGY AS A GROWTH INDUSTRY
The discoveries of biotechnology will soon be approaching 20 years of age. Several of the key discoveries—restriction enzymes (Kelly and 
Smith, 1970), DNA ligases (Weiss et al., 1968), etc. led to the first trans-
formed microbe in 1973 (Cohen et al., 1973). These initial discoveries led to 
an extended discussion, in 1976, in a San Francisco tavern between a venture 
capitalist Robert A. Swanson and Herbert W. Boyer of the University of Cali-
fornia in San Francisco. The first biotechnology-based “boutique,” Genentech, 
was thus soon formed. Genentech’s success led the way to the creation of 
hundreds of other small companies specializing in applications of an emerg-
ing technology—genetic engineering. The excitement, dreams and specula-
tion generated by this technology attracted billions of dollars of venture 
capital, primarily for human medical interests. By January 1, 1992, Amgen, 
one company of these origins, joined the Standard & Poor’s 500 and was 
given a $10 billion market evaluation.
The growing market of biotechnology-based protein drugs is now well- 
over $2 billion annually. In the late 1970s, interest in animal applications of 
biotechnology started to attract investments. Bovine somatotropin (BST) 
product development was the first direct spinoff of this early drug research 
activity. Many other applications of biotechnology for animals and plants 
have subsequently been the basis of the formation of small companies. Fed-
eral agencies directed close to $4 billion to support biotechnology research 
in 1992; this is of special interest to those of us interested in animal produc-
tion and the development of improved methods for enhancing the efficiency 
of production. Even more than that is being spent by hundreds of companies 
to develop further scientific bases and applications of biotechnology. Of tre- 
menendous potential for broadening the horizons for many aspects of biological 
research is the 15-year, $3 billion federal support of the Human Genome Project.
BIOTECHNOLOGY ADVANCES IN HUMAN MEDICINE AND SPINOFFS 
TO ANIMAL AGRICULTURE
Others in this conference will undoubtedly discuss the numerous and essen-
tial contributions of animal models to the development of human drugs and
treatment strategies for even the most intractable of the human disease con-
ditions. The following discussion will deal with certain aspects of the appli-
cations of biotechnology to animal research and agriculture.
In Table 1 is a list of protein drugs approved by the Food and Drug Ad-
ministration (FDA)since 1982, starting with Humulin®, a biosynthetic insu-
lin (Genetic Engineering News, January, 1992). Momentum in protein drugs is 
growing—5 of the 30 products approved by the FDA in 1991 were of this 
type. This rate may be duplicated in 1992 and possibly 100 more biotechnol-
TABLE i: BIOTECHNOLOGY-BASED DRUGS APPROVED BY FDA
Product Company Indication Year
Actimmune Genentech management of chronic 1990
granulomatous disease
Activase Genentech acute myocardial infarction 1987
acute pulmonary embolism 1990
Alferon Interferon Sciences genital warts 1989
Engenix SmithKlineBeechamhepatitis B 1989
Epogen Amgen 2 treatment of anemia associated with 1989
chronic renal failure, including 
patients on dialysis & not on 
dialysis, and anemia in Retrovir- 
trated HIV-infected patients
Procrit Ortho Biotech treatment of anemia associated with 1990
chronic renal failure, including 
patients on dialysis & not on 
dialysis, and anemia in Retrovir- 
trated HIV-infected pa lients
Humatrope Eli Lilly human growth hormone deficiency in 1987
children
Humulin Eli Lilly diabetes 1982
Intron Schering-Plough hairy cell leukemia 1986
genital warts 1988
AIDS-related Kaposi's sarcoma 1988
non-A, non-B hepatitis 1991
Leukine Immunex autologous bone marrow 1991
tranplantation
Prokine Hoechst-Rooussel autologous bone marrow transplan- 1991
tation
Neupogen Amgen chemotherapy-induced neutropenia 1991
Orthoclone OKT3 Ortho Biotech reversal of acute kidney transplant 1986
rejection
Protropin Genentech human growth hormone deficiency in 1985
children
Recombovax HB Merck hepatitis B prevention 1986
Roferon-A Hoffman-LaRoche hairy cell leukemia 1986
AIDS-related Kaposi’s sarcoma 1988
Animal Biotechnology.' Opportunities & Challenges
ogy-based drugs are now in clinical trials. Applications of identical or similar 
products for animals are bound to follow all of this activity. A major advan-
tage of this is that human drug development leads to initial reagents and test 
probes for studies both in vitro and in vivo in other animals.
Of longer-term consequence is the development of a large number of 
products resulting in significant production process developments and asso-
ciated discoveries which lead to reduced costs of drug production. In many 
cases, this alone permits consideration of new animal product concepts. Ad-
ditionally, some of these biosynthetic proteins are likely to have desirable ef-
fects during certain physiological states of animals not predicted from their 
names or the initial basis for their discovery.
The rapid development of genetic engineering has made it possible for a 
soaring rate of new discoveries. Proteins present in minute quantities, but 
occasionally of immense importance to animal physiology, can be predicted 
from messenger RNA. Thus, the existence of previously unknown proteins 
can be demonstrated by isolation and multiplication of very specific genetic 
codes. This has led to the discovery of numerous important proteins (i.e., 
hormones, receptors, enzymes) that otherwise would have been impossible 
to discover by classical endocrinology-based techniques, even before know-
ing the function of these proteins.
Within the lifetimes of many of us, the understanding of receptors on 
cells have evolved from essentially a concept to a specific protein or a family 
of proteins. These advances have, in many cases, replaced the need for phar-
macological classifications for receptor types such as the adrenergic recep-
tors which are subdivided according to their pharmacological response to 
epinephrine and non-epinephrine (Ahlquist, 1948). The genetic expression 
of a hormone receptor and binding characteristics of each of a family of re-
ceptor proteins can now be studied for cell type specificity, etc. (Laird et al., 
1991). The diversity of protein receptors has led to new strategies for drug 
design including the utilization of very powerful chemical tertiary structure 
software for predicting specific drug analogs with highly selective activity.
In some cases, possession of quantities of a specific receptor protein allows 
screening for specific binding by peptides or other chemicals to develop spe-
cific blockers.
As recently reported (Gibbons, 1992), second generation products from 
biotechnology will include other specific means of modifying selected pro-
tein expression. The expression of specific proteins which either inhibit 
growth enhancement or cause disease conditions may be reduced or elimi-
nated by blocking the transcription of DNA into the specific protein messen-
ger RNA. Another method of obtaining similar responses is to develop short 
oligonucleotides that recognize and bind to specific messenger RNAs and 
thus block protein synthesis. These and other means provide opportunities 
for developing drugs that enhance animal production and health.
Links to Human Health
SUMMARY
Human health-related research is leading the way to new technological 
breakthroughs, reagents, probes and general understanding of biological sys-
tems at a molecular level. An additional benefit will be the generation of 
many opportunities for enhancing animal production. In many cases, species 
specificities may be engineered into the developing strategies to ensure that 
human health concerns are met even at a molecular level. At the present time 
there are more opportunities for improving the efficiency and endproduct 
quality (e.g., nutritional value), than can be funded by most major compa-
nies. The many exciting advances in biotechnology are steadily making the 
discovery process more affordable and allowing the backlog of opportunities 
to build. Recognition and acceptance of how to safely apply biotechnolgically 
based productivity enhancers and health aids will surely result in much 
greater investment in animal drug development in the near future. All of this 
activity, plus the advances in animal science, will assure the world new meth-
ods of increasing the abundance, quality and variety of foods. Given the pre-
diction that 10 billion people may be on earth within the first half of the 21st 
century, this is an issue of great importance. These future products will be 
cheaper and safer to produce and will lead to superior, safer and environ-
mentally friendly management options for animal agriculture. All of these 
qualities should make these innovations available to more of the world’s food 
producers including those in developing countries.
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